X4 Pharmaceuticals Inc expected to post a loss of 24 cents a share - Earnings Preview

X4 Pharmaceuticals

17/03/2023 13:31

* X4 Pharmaceuticals Inc  XFOR.OQ   XFOR.O  is expected
to show no
change in quarterly revenue when it reports  results on March
21. 
    * 
    * ​Refinitiv's mean analyst estimate for X4 Pharmaceuticals
Inc is
for a loss of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $4.5​, above​ its last closing price
of $0.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.31       -0.30      -0.26     Beat    13.1
 Jun. 30 2022  -0.65       -0.64      -0.60     Beat    6
 Mar. 31 2022  -0.60       -0.61      -0.72     Missed  -18.3​
 Dec. 31 2021              -0.68      -0.90     Missed  -31.8
 ​​Sep.        -0.74       -0.72      -0.76     Missed  -5.2
 30 2021                                                
 Jun. 30 2021  -0.74       -0.74      -0.74     Met     -0.2​
 Mar. 31 2021  -0.89       -0.86      -1.30     Missed  -51.4
 Dec. 31 2020  -0.94       -0.90      -0.91     Missed  -0.8
 This summary was machine generated March 17 at 13:31 GMT.  All
figures in US dollars  unless otherwise stated